All Filters
Therapeutic Area
Therapeutic Area
Format
What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Format
top

Pluvicto▼(lutetium [177Lu] vipivotide tetraxetan) prescribing information
Locametz▼(gozetotide) prescribing information

 These links will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Hero banner. Pluvicto▼ (lutetium Lu 177 vipivotide tetraxetan) logo.
Hero banner. Pluvicto▼ (lutetium Lu 177 vipivotide tetraxetan) logo.

Mechanism of action (MoA)

Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1

Pluvicto is available in the United Kingdom to eligible private patients.

Locametz®▼ (gozetotide) is for diagnostic use only. Locametz, after radiolabelling with gallium-68, is a radioactive diagnostic agent indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions by positron emission tomography (PET) in adult patients with prostate cancer.2

Pluvicto is a PSMA-targeted radioligand therapy (RLT) that delivers DNA-damaging radiation to PSMA-positive bone, nodal, and visceral metastases.1,3–7

Pluvicto targets PSMA-positive cells, including prostate cancer cells.1

The MoA of Pluvicto can be broken down into a few key steps:

Pluvicto comprises 2 key components:

lutetium-177, a cytotoxic radionuclide, and PSMA-617, a PSMA-targeting ligand.1

Image to highlight how Pluvicto binds to PSMA on prostate cancer cells.

As determined by pre-clinical research, Pluvicto binds with high affinity to PSMA, a transmembrane protein overexpressed on prostate cancer cells.1

After binding to PSMA, Pluvicto undergoes endocytosis and is internalised into the cell.1,3

Image to highlight how Lutetium-177 emits DNA-damaging radiation within the cell causing single- and double-stranded DNA breaks in targeted cells as well as surrounding cells.

As determined by preclinical research, Lutetium-177, (the cytotoxic radionuclide of Pluvicto), emits DNA-damaging radiation within the cell.1,3,5

The short path length of the radiation emitted by Pluvicto (approx. 2 mm max.), causes single- and double-stranded DNA breaks in targeted cells as well as surrounding cells, which can lead to cell death.4,5,10

  • PSMA scanning enables you to see and target PSMA-positive mCRPC2,5,11,12

  • The high sensitivity of PSMA scanning detects PSMA-positive bone, nodal or visceral 
metastases11–14

  • PSMA imaging establishes patient eligibility for PSMA-targeted RLT6

The most common adverse reactions (≥20%) occurring at a higher incidence in patients who received Pluvicto + BSoC were fatigue (43.1%), dry mouth (39.3%), nausea (35.3%), anaemia (31.8%), decreased appetite (21.2%) and constipation (20.2%).1 Clinically relevant adverse reactions in <5% of patients included dry eye, vertigo and pancytopenia (including bicytopenia).1

Please refer to the Pluvicto Summary of Product Characteristics for full safety information.

Clinical trials page header showing an image of scientists in a lab.

Clinical trials

Clinical trials
See more details
Hide details
Dosing and administration page header.

Dosing and administration

Dosing and administration
See more details
Hide details

Green vertical divider icon
Safety profile

Green vertical divider icon
Contact us

177Lu, lutetium; ADR, adverse drug reaction; AR, androgen receptor; BSoC, best standard of care; DNA, deoxyribonucleic acid; mCRPC, metastatic castration-resistant prostate cancer; MoA, mechanism of action; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy.

References

  1. Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) Summary of Product Characteristics. 

  2. Locametz®▼ (gozetotide) Summary of Product Characteristics.

  3. Benešová M, et al. J Nucl Med 2015;56(6):914–920.

  4. Fendler WP, et al. J Nucl Med 2017;58(11):1786–1792.

  5. Hofman MS, et al. Lancet Oncol 2018;19(6):825–833.

  6. Sartor O, et al. N Engl J Med 2021;385(12):1091–1103.

  7. Violet J, et al. J Nucl Med 2019;60(4):517–523.

  8. Liu H, et al. Cancer Res 1998;58(18):4055–4060.

  9. Rajasekaran SA, et al. Mol Biol Cell 2003;14(12):4835–4845.

  10. Ruigrok EAM, et al. Eur J Nucl Med Mol Imaging 2021;48(5):1339–1350.

  11. Maffey-Steffan J, et al. Eur J Nucl Med Mol Imaging 2020;47(3):695–712.

  12. Vlachostergios PJ, et al. Front Oncol 2021;11:630589.

  13. Woythal N, et al. J Nucl Med 2018;59(2):238–243.

  14. Schmuck S, et al. J Nucl Med 2017;58(12):1962–1968.

 

UK | October 2025 | FA-11470709

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.